However, the BNIP3L gene is still of interest and a recent publication suggested a BNIP3L dependent pathway to be a target for cancer therapy in a subgroup of triple negative breast cancer [38]. This evidence concerns the gene BNIP3L and triple-negative breast carcinoma.